Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Other Non-Current Liabilities: 2021-2022

Historic Other Non-Current Liabilities for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $2.7 million.

  • Cardiol Therapeutics' Other Non-Current Liabilities fell 21.36% to $2.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $2.7 million, marking a year-over-year decrease of 21.36%. This contributed to the annual value of $3.3 million for FY2021, which is N/A change from last year.
  • According to the latest figures from Q3 2022, Cardiol Therapeutics' Other Non-Current Liabilities is $2.7 million, which was down 37.84% from $4.3 million recorded in Q2 2022.
  • Cardiol Therapeutics' 5-year Other Non-Current Liabilities high stood at $4.3 million for Q2 2022, and its period low was $2.7 million during Q3 2022.
  • Moreover, its 2-year median value for Other Non-Current Liabilities was $3.7 million (2021), whereas its average is $3.6 million.
  • Within the past 5 years, the most significant YoY rise in Cardiol Therapeutics' Other Non-Current Liabilities was 4.79% (2022), while the steepest drop was 21.36% (2022).
  • Over the past 2 years, Cardiol Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $3.3 million in 2021, then fell by 21.36% to $2.7 million in 2022.
  • Its Other Non-Current Liabilities was $2.7 million in Q3 2022, compared to $4.3 million in Q2 2022 and $3.9 million in Q1 2022.